Will an “off-year” drug price revision happen in April 2025 or not? Over the last week, expectations have been up…
BUSINESS
Broader Use of Blood Biomarkers Key to Maximizing Leqembi’s Value: Eisai Exec
Eisai’s global Alzheimer’s disease (AD) officer Keisuke Naito said on October 17 that sales of the company’s AD therapy Leqembi (lecanemab) are anticipated to expand sharply from FY2025 on the assumption that blood biomarkers will become widely available. The drug…
To read the full story
Related Article
- Eisai Cuts Leqembi Sales Target as It Sees “Some Delays” in US Uptake
November 11, 2024
- Eisai Sees Global Sales of Leqembi Surging to 56.5 Billion Yen in FY2024
May 16, 2024
- Leqembi Gathers Pace with Sales Up 2.7-Fold in January-March: Eisai
April 25, 2024
- Eisai CEO Confident in Leqembi Uptake, Says 90% of US Hospital Targets to Adopt Med by March-End
March 8, 2024
- 2,000 Patients Receiving Leqembi in US, 4 Times the Number on Wait List: Eisai
February 7, 2024
BUSINESS
- Jazz’s Epilepsy Drug Candidate Nearing Submission as Japan Lifts Ban on Cannabis-Derived Meds
December 18, 2024
- ASKA Begins Japan PIII for Relugolix Combo Drug
December 17, 2024
- Kyorin Licenses Novel OSA Treatment from Bayer
December 17, 2024
- Strattera and All Generic Versions Now under Supply Restrictions in Japan
December 17, 2024
- COVID Jab Kostaive Gets EMA Backing: Meiji
December 17, 2024
For 25 years, Morunda has been interviewing leaders in Japan’s pharmaceutical and medical device industry. Most country managers typically come from a commercial background, rooted in sales and marketing. It’s rare to find country managers who come from finance or…
A Japanese health ministry panel discussing the generic industry structure on May 22 put together a report in which it…
A Japanese health ministry study group focused on pharmaceutical regulations on March 21 agreed on a policy to encourage the…
The Japanese health ministry on December 22 approved a batch of medicines for additional indications, including Otsuka Pharmaceutical’s atypical antipsychotic Rexulti (brexpiprazole) and Zenyaku Kogyo’s anti-CD20 antibody Rituxan (rituximab).Rexulti is now newly indicated for the treatment of depression and depressive…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…
The Japanese health ministry’s expert panel tasked to discuss comprehensive policies for the rapid and stable supply of pharmaceuticals generally…
A key Japanese reimbursement policy panel on December 16 approved the government-backed plan for the FY2023 “off-year” drug price revision.…
Authorized generic (AG) strategies taken by innovative drug makers might help soften the impact of generic competition in their businesses but such tactics might also accelerate the application of “G1”/“G2” price cuts for their off-patent brand-name medicines, a Jiho tally…
Japan’s health ministry announced new NHI prices to be applied in April under the FY2022 drug price revision in the official gazette on March 4, with the earlier application of so-called “G1” price cuts to be implemented for the first…